BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22531127)

  • 1. Body size and risk for colorectal cancers showing BRAF mutations or microsatellite instability: a pooled analysis.
    Hughes LA; Williamson EJ; van Engeland M; Jenkins MA; Giles GG; Hopper JL; Southey MC; Young JP; Buchanan DD; Walsh MD; van den Brandt PA; Alexandra Goldbohm R; Weijenberg MP; English DR
    Int J Epidemiol; 2012 Aug; 41(4):1060-72. PubMed ID: 22531127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased cancer predisposition in family members of colorectal cancer patients harboring the p.V600E BRAF mutation: a population-based study.
    Wish TA; Hyde AJ; Parfrey PS; Green JS; Younghusband HB; Simms MI; Fontaine DG; Dicks EL; Stuckless SN; Gallinger S; McLaughlin JR; Woods MO; Green RC
    Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1831-9. PubMed ID: 20570909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.
    Kalady MF; Dejulius KL; Sanchez JA; Jarrar A; Liu X; Manilich E; Skacel M; Church JM
    Dis Colon Rectum; 2012 Feb; 55(2):128-33. PubMed ID: 22228154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer.
    Seppälä TT; Böhm JP; Friman M; Lahtinen L; Väyrynen VM; Liipo TK; Ristimäki AP; Kairaluoma MV; Kellokumpu IH; Kuopio TH; Mecklin JP
    Br J Cancer; 2015 Jun; 112(12):1966-75. PubMed ID: 25973534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype.
    English DR; Young JP; Simpson JA; Jenkins MA; Southey MC; Walsh MD; Buchanan DD; Barker MA; Haydon AM; Royce SG; Roberts A; Parry S; Hopper JL; Jass JJ; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2008 Jul; 17(7):1774-80. PubMed ID: 18628431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.
    Nakaji Y; Oki E; Nakanishi R; Ando K; Sugiyama M; Nakashima Y; Yamashita N; Saeki H; Oda Y; Maehara Y
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):151-160. PubMed ID: 27672042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marine ω-3 polyunsaturated fatty acids and risk of colorectal cancer according to microsatellite instability.
    Song M; Nishihara R; Wu K; Qian ZR; Kim SA; Sukawa Y; Mima K; Inamura K; Masuda A; Yang J; Fuchs CS; Giovannucci EL; Ogino S; Chan AT
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25810492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes.
    Limsui D; Vierkant RA; Tillmans LS; Wang AH; Weisenberger DJ; Laird PW; Lynch CF; Anderson KE; French AJ; Haile RW; Harnack LJ; Potter JD; Slager SL; Smyrk TC; Thibodeau SN; Cerhan JR; Limburg PJ
    J Natl Cancer Inst; 2010 Jul; 102(14):1012-22. PubMed ID: 20587792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
    de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
    Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.
    Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Takahashi A; Kakuta M; Nishimura Y; Yamaguchi K
    J Surg Oncol; 2014 Dec; 110(8):982-8. PubMed ID: 25154726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic BRAF-V600E mutations in familial colorectal cancer.
    Vandrovcova J; Lagerstedt-Robinsson K; Påhlman L; Lindblom A
    Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2270-3. PubMed ID: 17119056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.
    Tie J; Gibbs P; Lipton L; Christie M; Jorissen RN; Burgess AW; Croxford M; Jones I; Langland R; Kosmider S; McKay D; Bollag G; Nolop K; Sieber OM; Desai J
    Int J Cancer; 2011 May; 128(9):2075-84. PubMed ID: 20635392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of anthropometric factors with KRAS and BRAF mutation status of primary colorectal cancer in men and women: a cohort study.
    Brändstedt J; Wangefjord S; Nodin B; Eberhard J; Sundström M; Manjer J; Jirström K
    PLoS One; 2014; 9(2):e98964. PubMed ID: 24918610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MSI status is associated with distinct clinicopathological features in BRAF mutation colorectal cancer: A systematic review and meta-analysis.
    Wu M; Kim YS; Ryu HS; Choi SC; Kim KY; Park WC; Kim MS; Myung JY; Choi HS; Kim EJ; Lee MY
    Pathol Res Pract; 2020 Jan; 216(1):152791. PubMed ID: 31866097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics.
    Phipps AI; Buchanan DD; Makar KW; Burnett-Hartman AN; Coghill AE; Passarelli MN; Baron JA; Ahnen DJ; Win AK; Potter JD; Newcomb PA
    Cancer Epidemiol Biomarkers Prev; 2012 Oct; 21(10):1792-8. PubMed ID: 22899730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
    Preto A; Figueiredo J; Velho S; Ribeiro AS; Soares P; Oliveira C; Seruca R
    J Pathol; 2008 Feb; 214(3):320-7. PubMed ID: 18098337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
    Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
    Hum Pathol; 2007 Jun; 38(6):842-9. PubMed ID: 17350669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk Factors and Incidence of Colorectal Cancer According to Major Molecular Subtypes.
    Wang L; He X; Ugai T; Haruki K; Lo CH; Hang D; Akimoto N; Fujiyoshi K; Wang M; Fuchs CS; Meyerhardt JA; Zhang X; Wu K; Chan AT; Giovannucci EL; Ogino S; Song M
    JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33442661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.
    Dahlin AM; Palmqvist R; Henriksson ML; Jacobsson M; Eklöf V; Rutegård J; Oberg A; Van Guelpen BR
    Clin Cancer Res; 2010 Mar; 16(6):1845-55. PubMed ID: 20197478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women.
    Limsui D; Vierkant RA; Tillmans LS; Wang AH; Weisenberger DJ; Laird PW; Lynch CF; Anderson KE; French AJ; Haile RW; Harnack LJ; Potter JD; Slager SL; Smyrk TC; Thibodeau SN; Cerhan JR; Limburg PJ
    Gut; 2012 Sep; 61(9):1299-305. PubMed ID: 22027477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.